Oxford BioTherapeutics
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
    • PUBLICATIONS
  • CAREERS
  • NEWS
    • PRESS RELEASES
    • OBT in the News
  • CONTACT

Harnessing immune cells to cure cancer 

Redefining the cancer-immune synapse for
novel immune checkpoint mechanisms 
NOVEL IO DISCOVERIES
Pipelines

Immunotherapies for Cancer


​Oxford BioTherapeutics (OBT) is a clinical stage oncology company focussed only on first-in-class immune therapies, with special emphasis on improving outcomes for patients with solid tumors who respond poorly to PD-1 inhibitors. 

Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development.

OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. 

Our clinical and pre-clinical pipeline of novel immunotherapies is balanced between internal programs, focused on ADCs and checkpoint regulators, and externally partnered programs with key innovators in oncology such as Boehringer Ingelheim and Kite, a Gilead company. 

Our OGAP
® platform is the world's largest, cancer specific, membrane protein library, directly measuring plasma membrane protein expression in patient tumors. OGAP is used to identify novel, highly tumor specific antigens for novel first-in-class ADC, Bispecific T-cell Engager (BITE®) and Chimeric Antigen Receptor (CAR) targets.
Picture

GLOBAL HEADQUARTERS

94a Innovation Drive
Milton Park
Abingdon OX14 4RZ
UK
+44-1235-861-770

CONTACT US

US OPERATIONS

San Jose Biocenter
5941 Optical Court
San Jose, CA 95138
USA
+1-408-960-7461
CONTACT US

Privacy Policy

Legal Notice

Site Map

© 2017 Oxford BioTherapeutics All Rights Reserved
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
    • PUBLICATIONS
  • CAREERS
  • NEWS
    • PRESS RELEASES
    • OBT in the News
  • CONTACT